Advances In Genomics And AI Will Expand Rare Disease Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 21 Analysts
Published
10 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$85.92
42.9% undervalued intrinsic discount21 Aug
US$49.08
1Y
93.9%7D
-4.4%